A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy Volunteers
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This single-dose, randomized, open-label, 2-sequence, 3-period study will evaluate the effect
of cyclosporine on the pharmacokinetics of ritonavir-boosted danoprevir (DNV/r) in healthy
volunteers. Subjects will be randomized to one of two treatment sequences to receive a single
oral dose of DNV/r or cyclosporine. In treatment period 3, subjects will receive a single
oral dose of DNV/r plus cyclosporine. Anticipated time on study is 33 days.